AGO recommendations for the diagnosis and treatment of patients with early breast cancer: Update 2014

Breast Care

Volumn 9, Issue 3, 2014, Pages 189-200

  Liedtke, Cornelia ^a   Thill, Marc ^b   Hanf, Volker ^c   Schütz, Florian ^d  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

^c KLINIKUM FÜRTH   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Adjuvant treatment; Breast cancer; Surgery; Treatment recommendations

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTHRACYCLINE; BRCA1 PROTEIN; BRCA2 PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PEGFILGRASTIM; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; RALOXIFENE;

ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST CANCER; BREAST METASTASIS; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER THERAPY; EARLY CANCER; FAMILIAL CANCER; HUMAN; INTRADUCTAL CARCINOMA; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ADJUVANT CHEMOTHERAPY; AXILLARY LYMPH NODE; CANCER INCIDENCE; ECHOGRAPHY; ECHOMAMMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; FINE NEEDLE ASPIRATION BIOPSY; GENE DOSAGE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HIGH RISK POPULATION; HORMONAL THERAPY; INJECTION; INTERMEDIATE RISK POPULATION; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PARTIAL MASTECTOMY; PLASTIC SURGERY; RISK FACTOR; SALPINGOOOPHORECTOMY; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84904665583     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000363591     Document Type: Article

References (110)

1. Centre for Evidence Based Medicine: Oxford Level of Evidence LoE. www.cebm.net
2. www.ago-online.de/de/fuer-mediziner/leitlinienempfehlungen/mamma
3. Ritte R, Tikk K, Lukanova A, et al.: Reproductive factors and risk of hormone receptor positive and negative breast cancer: A cohort study. BMC Cancer 2013;13:584
4. Gonzalez CA: Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer 2010;46:2555-2562
5. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al.: Diabetes, metformin and breast cancer in postmenopausal women. J Clin Oncol 2012;30: 2844-2852
6. McDonald JA, Goyal A, Terry MB: Alcohol intake and breast cancer risk: Weighing the overall evidence. Curr Breast Cancer Rep 2013;5(3).
7. Moorman PG, Havrilesky LJ, Gierisch JM: Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis. J Clin Oncol 2013;31: 4188-4198
8. Plon SE, Eccles DM, Easton D, et al.: Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008; 29:1282-1291
9. Gaudet MM, Kirchhoff T, Green T, et al.: Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010;6:e1001183. immunotherapeu
10. Couch FJ, Wang X, McGuffog L, et al.: Genomewide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013;9:e1003212
11. Mavaddat N, Barrowdale D, Andrulis IL, et al.: Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012;21:134-147
12. Garcia-Closas M, Chanock S: Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008;14:8000-8009
13. Weischer M, Nordestgaard BG, Pharoah P, et al.: CHEK2. 1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 2012;30:4308-4316
14. Gartlehner G, Thaler K, Chapman A, et al.: Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev 2013;(4):CD009632
15. De Bock GH, Vermeulen KM, Jansen L, et al.: Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations?. A simulation of comparative cost-effectiveness. Br J Cancer 2013;108:1579-1586
16. Bosse K, Graeser M, Goßmann A, et al.: Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 2014;289:663-670
17. Fischer T, Sack I, Thomas A: Characterization of focal breast lesions by means of elastography. Röfo 2013;185:816-823
18. Houssami N, Turner R, Macaskill P, et al.: An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 2014;32:392-401
19. Houssami N, Turner R, Morrow M: Preoperative magnetic resonance imaging in breast cancer: Meta- analysis of surgical outcomes. Ann Surg 2013; 257:249-255
20. Krekel NM, Haloua MH, Lopes Cardozo AM, et al.: Intraoperative ultrasound guidance for palpable breast cancer excision (COBALT trial): A multicentre, randomised controlled trial. Lancet Oncol 2013;14:48-54
21. Pan H, Wu N, Ding H, et al.: Intraoperative ultrasound guidance is associated with clear lumpectomy margins for breast cancer: A systematic review and meta-analysis. PLoS One 2013;8:e74028
22. Houssami N, Diepstraten SC, Cody HS 3rd, et al.: Clinical utility of ultrasound-needle biopsy for preoperative staging of the axilla in invasive breast cancer. Anticancer Res 2014;34:1087-1097
23. De Los Santos J, Cantor A, Amos KD, et al.: Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium Trial 017. Cancer 2013;15:1776-1783
24. Lobbes MBI, Prevos R, Smidt M, et al.: The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: A systematic review. Insights Imaging 2013; 4:163-175
25. Marinovich ML, Houssami N, Macaskill P, et al.: Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 2013;105:321-333
26. Marinovich ML, Sardanelli F, Ciatto S, et al.: Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of accuracy of MRI. Breast 2012;21:669-677
27. Richard R, Thomassin I, Chapellier M, et al.: Diffusion- weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 2013;23:2420-2431
28. Wolff AC, Hammond ME, Hicks DG, et al.; American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013
29. Rakha EA, Starczynski J, Lee AH, et al.: The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: A critical review of their implications for routine practice. Histopathology 2014;64:609-615
30. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-1452
31. Harbeck N, Schmitt M, Meisner C, et al.; Chemo- N0 Study Group: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013;49:1825-1835
32. Gnant M, Filipits M, Greil R, et al.; Austrian Breast and Colorectal Cancer Study Group: Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014;25:339-345
33. Sestak I, Cuzick J, Dowsett M, et al.: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score. SABCS 2013;abstr S6-04
34. Dubsky P, Brase JC, Jakesz R, et al.; Austrian Breast and Colorectal Cancer Study Group (ABCSG): The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013;109:2959-2964
35. Bidard F-C, Peeters D, Fehm T, et al.: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data. SABCS 2013;abstr
36. Perry N, Broeders M, De Wolf C, et al. (eds): European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis, ed 4. Luxembourg, European Commission, Office for Official Publications of the European Communities, 2006
37. Ceugnart L, Doualliez V, Chauvet MP, et al.: Pure flat epithelial atypia: Is there a place for routine surgery?. Diagn Interv Imaging 2013;94:861-869
38. Chivukula M, Haynik DM, Brufsky A, et al.: Pleomorphic lobular carcinoma in situ (pLCIS) on breast core needle biopsies: Clinical significance and immunoprofile. Am J Surg Pathol2008;32: 1721-1726
39. Shin SJ, Lal A, De Vries S, et al.: Florid lobular carcinoma in situ: Molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol 2013;44:1998-2009
40. Ross DS, Hoda SA: Microinvasive (T1mic) lobular carcinoma of the breast: Clinicopathologic profile of 16 cases. Am J Surg Pathol 2011;35:750-756
41. Bratthauer GL, Tavassoli FA: Lobular intraepithelial neoplasia: Previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch 2002;440:134-138
42. Shin SJ, Rosen PP: Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med 2002; 126:697-701
43. Elsheikh TM, Silverman JF: Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: A correlative study of 33 patients with review of the literature. Am J Surg Pathol 2005; 29:534-543
44. Nagi C: Lobular neoplasia on core needle biopsy does not require excision. Cancer 2008;112:2152-2158
45. Sohn V: Lobular neoplasia: Is surgical excision warranted?. Am Surg 2008;74:172-177
46. Cangiarella J: Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core biopsy?. Arch Pathol Lab Med 2008;132:979-983
47. Pinder S: Lobular in situ neoplasia and columnar cell lesions: Diagnosis in breast core biopsies and implications for management. Pathology 2007;39: 208-216
48. Brem R: Lobular neoplasia at percutaneous breast biopsy: Variables associated with carcinoma at surgical excision. AJR Am J Roentgenol 2008;190:637-641
49. www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf
50. Veronesi U, Luini A, Botteri E, et al.: Nonpalpable breast carcinomas: Long-term evaluation of 1,258 cases. Oncologist 2010;15:1248-1252
51. Morrow M, Jagsi R, Alderman AK, et al.: Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 2009;302: 1551-1556
52. Meijnen P, Oldenburg HS, Peterse JL, et al.: Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 2008;15:235-243
53. Dillon MF, Mc Dermott EW, O'Doherty A, et al.: Factors affecting successful breast conservation for ductal carcinoma in situ. Ann Surg Oncol 2007; 14:1618-1628
54. Dillon MF, Maguire AA, McDermott EW, et al.: Needle core biopsy characteristics identify patients at risk of compromised margins in breast conservation surgery. Mod Pathol 2008;21:39-45
55. Ahmed M, Douek M: Intra-operative ultrasound versus wire-guided localization in the surgical management of non-palpable breast cancers: Systematic review and meta-analysis. Breast Cancer Res Treat 2013;140:435-446
56. Goodwin A, Parker S, Ghersi D, Wilcken N: Post- operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2013;(11):CD000563
57. Solin LJ, Gray R, Baehner FL, et al.: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013;105:701-710
58. Siziopikou KP, Anderson SJ, Cobleigh MA, et al.: Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat 2013;142:415-421
59. Veronesi U, Viale G, Paganelli G, et al.: Sentinel lymph node biopsy in breast cancer: Ten-year results of a randomized controlled study. Ann Surg 2010;251:595-600
60. Boughey JC, Suman VJ, Mittendorf EA, et al.: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310:1455-1461
61. Kuehn T, Bauerfeind I, Fehm T, et al.: Sentinellymph- node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy ( SENTINA): A prospective, multicentre cohort study. Lancet Oncol 2013;14:609-618
62. Rutgers E, Donker M, Straver ME, et al.: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023). J Clin Oncol 2013;31(suppl):abstr LBA 1001
63. Agrawal A, Sibbering DM, Courtney CA: Skin sparing mastectomy and immediate breast reconstruction: A review. Eur J Surg Oncol 2013;39:320-328
64. Vaughn CJ, Peled AW, Esserman LJ, Foster RD: Feasibility of performing total skin-sparing mastectomy in patients with prior circumareolar mastopexy or reduction mammoplasty incisions. Ann Plast Surg 2013, Jun 19 [Epub ahead of print].
65. Hanna KR, DeGeorge BR Jr, Mericli AF, et al.: Comparison study of two types of expander- based breast reconstruction: Acellular dermal matrix-assisted versus total submuscular placement. Ann Plast Surg 2013;70:10-15
66. Dieterich M, Reimer T, Dieterich H, et al.: A short-term follow-up of implant based breast reconstruction using a titanium-coated polypropylene mesh (TiLoop(®) Bra). Eur J Surg Oncol 2012; 38:1225-1230
67. Bonomi R, Betal D, Rapisarda IF, et al.: Role of lipomodelling in improving aesthetic outcomes in patients undergoing immediate and delayed reconstructive breast surgery. Eur J Surg Oncol 2013; 39:1039-1045
68. Lohsiriwat V, Curigliano G, Rietjens M, et al.: Autologous fat transplantation in patients with breast cancer: 'silencing' or 'fuelling' cancer recurrence?. Breast 2011;20:351-357
69. Rigotti G, Marchi A, Stringhini P, et al.: Determining the oncological risk of autologous lipoaspirate grafting for post-mastectomy breast reconstruction. Ann Plast Surg 2010;34:475-480
70. Petit JY, Rietjens M, Botteri E, et al.: Evaluation of fat grafting safety in patients with intra epithelial neoplasia: A matched cohort study. Ann Oncol 2013;24:1479-1484
71. Krumboeck A, Giovanoli P, Plock JA: Fat grafting and stem cell enhanced fat grafting to the breast under oncological aspects - recommendations for patient selection. Breast 2013;22:579-584
72. Den Heijer M, van Asperen CJ, Harris H, et al.: International variation in physicians' attitudes towards prophylactic mastectomy - comparison between France, Germany, The Netherlands and the United Kingdom. Eur J Cancer 2013;49: 2798-2805
73. Davies C, Pan H, Godwin J, et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-816
74. Gray RG, Handley K, Bowden SJ, et al.: ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. ASCO 2013;abstr.
75. Goss PE, Ingle JN, Martino S, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802
76. Cognetti F, Bruzzi P, De Placido S, et al.: Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the Gruppo Italiano Mammella (GIM)-2 randomized phase III study. SABCS 2013;abstr S5-06
77. Swain SM, Tang G, Geyer CE, et al.: Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The NSABP B-38 trial. J Clin Oncol 2013;31:3197-3204
78. Budd GT, Barlow WE, Moore HCF, et al.: Comparison of two schedules of paclitaxel for adjuvant therapy of breast cancer. ASCO 2013;abstr.
79. Sparano JA, Wang M, Martino S, et al.: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-1671
80. Moebus V, Jackisch C, Lueck HJ, et al.: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. J Clin Oncol 2010;28: 2874-2880
81. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684
82. Perez EA, Suman VJ, Davidson NE, et al.: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29:4491-4497
83. Slamon D, Eiermann W, Robert N, et al.; Breast Cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283
84. Tolaney SM, Barry WT, Dang CT, et al.: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). SABCS 2013;abstr S1-04
85. Donker M, Litière S, Werutsky G, et al.: Breastconserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31:4054-4059
86. Hughes KS, Schaper LA, Bellon JR, et al.: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382-2387
87. Hwang ES, Lichtensztajn DY, Gomez SL, et al.: Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status. Cancer 2013;119: 1402-1411
88. Souchon R, Sautter-Bihl M-L, Sedlmayer F, et al.: DEGRO practical guidelines: Radiotherapy of breast cancer II - radiotherapy of non-invasive neoplasia of the breast. Strahlenther Onkol 2014; 190:8-16
89. van De Water W, Bastiaannet E, Scholten AN, et al.: Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: A systematic review and metaanalysis. Ann Surg Oncol 2014;21:786-794
90. Aristei C, Palumbo I, Capezzali G, et al.: Outcome of a phase II prospective study on partial breast irradiation with interstitial multi-catheter highdose rate brachytherapy. Radiother Oncol 2013; 108:236-241
91. Krengli M, Calvo FA, Sedlmayer F, et al.: Clinical and technical characteristics of intraoperative radiotherapy: Analysis of the ISIORT-Europe database. Strahlenther Onkol 2013;189:729-737
92. Leonardi MC, Maisonneuve P, Mastropasqua MG, et al.: Accelerated partial breast irradiation with intraoperative electrons: Using GEC-ESTRO recommendations as guidance for patient selection. Radiother Oncol 2013;106:21-27
93. Olivotto IA, Whelan TJ, Parpia S, et al.: Interim cosmetic and toxicity results from RAPID: A randomised trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiotherapy. J Clin Oncol 2013;31:4038-4045
94. Polgar C, Fodor J, Major T, et al.: Breast-conserving therapy with partial or whole breast irradiation: Ten-year results of the Budapest randomized trial. Radiother Oncol 2013;108:197-202
95. Vaidya JS, Wenz F, Bulsara M, et al.: Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014;383:603-613
96. Veronesi U, Orecchia R, Maisonneuve P, et al.: Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): A randomised controlled equivalence trial. Lancet Oncol 2013;14:1269-1277
97. Haviland JS, Owen R, Dewar J, et al.: The UK Standardisation of Breast Radiotherapy (START) trials of hypofractionating for treatment of early breast cancer: 10-year follow-up results of two randomized controlled trials. Lancet Oncol 2013;14:1086-1094
98. Haffty BG, Buchholz TA: Hypofractionated breast radiation: Preferred standard of care?. Lancet Oncol 2013;14:1032-1034
99. Herbert C, Nichol A, Olivotto I, et al.: The impact of hypofractionated whole breast radiotherapy on local relapse in patients with grade 3 early breast cancer: A population-based cohort study. Int J Radiat Oncol 2012;82:2086-2092
100. Whelan TJ, Pignol JP, Levine MN, et al.: Longterm results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513-520
101. Sedlmayer F, Sautter-Bihl ML, Budach W, et al.: DEGRO practical guidelines: Radiotherapy of breast cancer I: Radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol 2013;189:825-833
102. Chen X, Yu X, Chen J, et al.: Radiotherapy can improve the disease-free survival rate in triplenegative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist 2013;18:141-147
103. Li Y, Moran MS, Huo Q, et al.: Post-mastectomy radiotherapy for breast cancer patients with T1- T2 and 1-3 positive lymph nodes: A meta-analysis. PLoS One 2013;8:e81765
104. Moo TA, McMillan R, Lee M, et al.: Selection criteria for postmastectomy radiotherapy in T1- T2 tumors with 1 to 3 positive lymph nodes. Ann Surg Oncol 2013;20:3169-3174
105. Shim SJ, Park W, Huh SJ, et al.: The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: A multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys 2014;88:65-72
106. Liu D, Chen Y, Deng M, et al.: Lymph node ratio and breast cancer prognosis: A meta-analysis. Breast Cancer 2014;21:1-9
107. Saquib J, Parker BA, Natarajan L, et al.: Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer. Complement Ther Med 2012;20:283-290
108. Qi CJ, Ning YL, Han YS, et al.: Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother 2012;61:1415-1424
109. Montero AJ, Diaz-Montero CM, Deutsch YE, et al.: Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat 2012; 132:215-223
110. Adams S, Kozhaya L, Martiniuk F, et al.: Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 2012;18:6748-6757.